Latest Non Small Cell Lung Cancer News

Page 2 of 4
Radiopharm Theranostics has reported promising interim results from its Phase 2b trial of RAD 101, showing high concordance with MRI in brain metastases patients, while progressing multiple other clinical programs and securing a strong cash position to fund operations into 2027.
Ada Torres
Ada Torres
28 Jan 2026
Racura Oncology has launched a strategic collaboration with Emory University to investigate (E,E)-bisantrene’s potential to overcome resistance to osimertinib in EGFR-mutated non-small cell lung cancer. This partnership aims to bolster Racura’s HARNESS-1 clinical trial and strengthen its position in the competitive lung cancer treatment landscape.
Ada Torres
Ada Torres
14 Jan 2026
Racura Oncology has appointed Beyond Drug Development to oversee its HARNESS-1 Phase 1a/b trial combining RC220 with osimertinib in EGFR-mutated non-small cell lung cancer patients, marking a key step toward clinical advancement.
Ada Torres
Ada Torres
24 Dec 2025
Immutep Limited reports robust progress in its pivotal Phase III TACTI-004 trial for advanced non-small cell lung cancer, with over 120 clinical sites activated across 27 countries including the US. Patient enrolment has reached 38% of the target, keeping key milestones on track.
Ada Torres
Ada Torres
16 Dec 2025
Race Oncology has raised $3.22 million through a private placement to fund its HARNESS-1 Phase 1a/b trial targeting non-small cell lung cancer, with patient enrolment expected early next year.
Ada Torres
Ada Torres
9 Dec 2025
Immutep has struck a strategic licensing deal with Dr. Reddy’s, granting rights to commercialise its novel cancer immunotherapy Eftilagimod Alfa across key emerging markets. The agreement includes a $20 million upfront payment and potential milestones exceeding $349 million.
Ada Torres
Ada Torres
8 Dec 2025
Immutep Limited reveals promising Phase II results from its AIPAC-003 trial, establishing 30 mg as the optimal biological dose of eftilagimod alfa combined with paclitaxel in metastatic breast cancer patients.
Ada Torres
Ada Torres
2 Dec 2025
Race Oncology has received ethics approval to launch its HARNESS-1 Phase 1a/b trial testing RC220 combined with osimertinib in EGFR-mutated non-small cell lung cancer patients, marking a key step toward addressing resistance to current therapies.
Ada Torres
Ada Torres
26 Nov 2025
Race Oncology has announced pivotal new clinical trials for its lead asset RC220, aiming to accelerate regulatory approval in Acute Myeloid Leukemia and tackle resistance in Non-Small Cell Lung Cancer.
Ada Torres
Ada Torres
17 Nov 2025
Radiopharm Theranostics has successfully enrolled the second cohort in its Phase 1 trial of 177Lu-RAD204, with the Data Safety Monitoring Committee greenlighting a dose increase to 90mCi for the third cohort. Early results show promising tumor targeting and safety in multiple advanced cancers.
Ada Torres
Ada Torres
12 Nov 2025
Percheron Therapeutics reports encouraging phase I clinical results for HMBD-002, confirming safety and early efficacy signals, while gearing up for a multi-arm phase II trial in 2026.
Ada Torres
Ada Torres
31 Oct 2025
Immutep Limited reports strong progress in its Phase III lung cancer trial with over 170 patients enrolled, alongside positive FDA feedback and a robust cash position supporting ongoing development.
Ada Torres
Ada Torres
29 Oct 2025